Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors

Simultaneous inhibition of multiple molecular targets is an established strategy to improve the continuance of clinical response to therapy. Here, we screened 49 molecules with dual nanomolar inhibitory activity against BRD4 and PLK1, best classified as dual kinase-bromodomain inhibitors, in pediatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Timme, Natalie, Han, Youjia, Liu, Shuai, Yosief, Hailemichael O., García, Heathcliff Dorado, Bei, Yi, Klironomos, Filippos, MacArthur, Ian C., Szymansky, Annabell, von Stebut, Jennifer, Bardinet, Victor, Dohna, Constantin, Künkele, Annette, Rolff, Jana, Hundsdörfer, Patrick, Lissat, Andrej, Seifert, Georg, Eggert, Angelika, Schulte, Johannes H., Zhang, Wei, Henssen, Anton G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931204/
https://www.ncbi.nlm.nih.gov/pubmed/31869746
http://dx.doi.org/10.1016/j.tranon.2019.09.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931204/
https://www.ncbi.nlm.nih.gov/pubmed/31869746
http://dx.doi.org/10.1016/j.tranon.2019.09.013

Ejemplares similares